Navigation Links
Myoglobin Test Modules

ProductsMyoglobin Test Modules
Company Dade Behring, Inc.
Item Myoglobin Test Modules
Features 
Description A fluorogenic enzyme-linked immunoassay (ELISA) for the quantitative measurement of myoglobin in human serum or plasma aiding in the diagnosis of acute myocardial infarction (AMI). Features : Dry chemistry-based technology for ease of use.
Info Dade Behring, Inc.Call Dade Behring, Inc. to buy products (US and Canada only; other locations use number below) USACanada1-866-262-8155

Customer Service: 1-847-267-5300
Web site: http://www.dadebehring.com

Related medicine products :

1. Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease
2. Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease
3. Human Myoglobin Enzyme Immunoassay
4. Myoglobin ELISA
5. Myoglobin IRMA Kit
6. Myocardial Infarction - Myoglobin and Troponin Cassette
7. Myoglobin Assay for the VITROS ECi Immunodiagnostic System
8. CARDIAC M Myoglobin
9. AxSYM Myoglobin
10. Acute Care Myoglobin TestPak
11. Myoglobin Immunoassay Kit
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers.
Each handle is designed to fit a specific trephine size.
Each handle is designed to fit a specific trephine size.
Each handle is designed to fit a specific trephine size.
Medicine Products:
(Date:8/7/2008)...gh Tissue Engineering Initiative Marks 12th Year o... PITTSBURGH, Aug. 7 /PRNewswire/ -- Twenty-four u...es, primarily across southwestern Pennsylvania,and...h annual Summer,Internship Program of the Pittsbur...of the program is to expose greatly increased numb...
(Date:8/7/2008)...TY, Aug. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKli...rom the HEAT study show that,once-daily EPZICOM (a... to,once-daily Truvada(R) (tenofovir DF + emtricit... HIV. The data were presented today at the 17th,In...., HEAT is the first large, prospective, long-ter...
(Date:8/7/2008)...N, Aug. 7 /PRNewswire-USNewswire/ -- The U.S. Gove...Development (USAID), is providing,an initial $50,0...emergency,relief supplies to the flood-affected po...ains led to flooding in central and,southeastern T...he capital,of Lome. The UN Development Program est...
(Date:8/7/2008)... Crohn,s disease (CD) are seven-fold more likely t...ses a digestive-tract disease in cattle called Joh...not play in causing CD is a top research priority,...n Academy of Microbiology. The reports points out... role of this bacteriumwhich could conceivably be ...
Breaking Medicine News(10 mins):Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 2Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 4Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 5Health News:Pathogen that causes disease in cattle also associated with Crohn's disease 2
... of deaths from advanced prostate cancer is to cat...A recent study suggests that effective screening c...is the most frequently diagnosed cancer in men and...by cancer in men in the USA. Many of these cancers...
...id to be able to block the HIV virus from entering... This maybe a major step forward in treatment of...oto, have announce ground braking news in the figh... headed by Hiroaki Mitsuya tried the new drug on 4...
...em are often treated with inhaled nitric oxide// t...at this therapy does not reduce the chances of dea... study are of opinion that premature babies who we...n inhaled nitric oxide therapy unless they are the...
...ceptives maybe at increased risk of heart attack/...k disappears if they stop the pill. The study done... in the July issue of the Journal of Clinical Endo... could have further significance for those women t...
Other Medicine News:Health News:Screening For Prostate Cancer May Reduce Mortality Rate 2Health News:Low-Dose Oral Contraceptives May Increase Risk For Heart Attack Or Stroke 2
(Date:8/5/2008)... NEW HAVEN, Conn., Aug. 5 /- Rib-..., a development-stage company focused on the,disco...treatment of,antibiotic-resistant infections, anno...g three presentations at two conferences this,week...try, August 3-8, Ashoke Bhattacharjee, Ph.D, Seni...
(Date:8/5/2008)... National trial aims to help heart failure pat...r clot risk and less blood damage than,earlier hea...USNewswire/ -- Anthony Shannon,made history on Jul...e,United States to receive a new type of experimen... a DuraHeart, it was implanted in his chest, and,c...
(Date:8/5/2008)... - Phase IIb study examines efficacy and safety...t-naive adults with HIV-1 -, MEXICO CITY, Aug. 5 ...armaceuticals Ltd. provides additional information...,s once-daily, investigational,non-nucleoside reve...V,combination therapy in treatment-naive adults. T...
(Date:8/5/2008)... - $25 Million Interferon-Beta-CTP Development Pro...ough a Special Grant From the Israeli Office of th...S-ZIONA, Israel, Aug. 5 /- ...orted that its Israeli-based R&D subsidiary,has re...li Office of the,Chief Scientist ("OCS") in suppor...
Breaking Medicine Technology:Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 2Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 3First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 2First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 3First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 4Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008 2Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 2Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 3Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta 4Highlights of Economic and Business Growth in the Tampa Bay Region 800 1Highlights of Economic and Business Growth in the Tampa Bay Region 800 2Highlights of Economic and Business Growth in the Tampa Bay Region 800 3Highlights of Economic and Business Growth in the Tampa Bay Region 800 4Explorer completes the map for the bodys blueprint 1937 1Explorer completes the map for the bodys blueprint 1937 2MR spectroscopy identifies breast cancer reduces biopsies 1935 1MR spectroscopy identifies breast cancer reduces biopsies 1935 2Pelosi 3A Mr President Drop the Partisan Rhetoric Put Down the Veto Pen 1933 1
...USINESS WIRE)--Jun 13, 2007 - EPIX,Pharmaceuticals...om,its Phase 3 trial of PRX-00023, a novel long-ac...entation at the 47th Annual New,Clinical Drug Eval.... The meeting is sponsored by the National Institu... Psychopharmacology., The presentation highlighted...
...--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite,BioPhar...the Tel,Aviv Stock Exchange Exchange, proceeds wit... in addition to CF101, which is currently,in clini...es. This,weekend Can-Fite will present at the EUAL...vivo study results showing effective,anti-inflamma...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology 2